<DOC>
	<DOCNO>NCT01852292</DOCNO>
	<brief_summary>Phase II Study efficacy safety buparlisib ( BKM120 ) plus paclitaxel versus placebo plus paclitaxel recurrent metastatic Head Neck cancer previously pre-treated platinum therapy .</brief_summary>
	<brief_title>Study Efficacy Safety Buparlisib ( BKM120 ) Plus Paclitaxel Versus Placebo Plus Paclitaxel Recurrent Metastatic Head Neck Cancer Previously Pre-treated With Platinum Therapy</brief_title>
	<detailed_description>The primary endpoint PFS key secondary endpoint Overall Survival .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patient histologically/cytologicallyconfirmed HNSCC . Patient archival fresh tumor tissue analysis PI3Krelated biomarkers . One tumor block ( prefer ) minimum 12 unstained slide provide . Enrollment study contingent confirmation adequate amount tumor tissue . Patients recurrent metastatic disease resistant platinumbased chemotherapy ( define progression platinumbased chemotherapy give recurrent/metastatic setting ) . Pretreatment cetuximab allow Measurable disease determine per RECIST criterion v1.1 . If site measurable disease previously irradiate lesion , document progression disease 4 week period since radiotherapy completion require Adequate bone marrow function organ function ECOG Performance Status ≤ 1 Patient receive previous treatment AKT , mTOR inhibitor PI3K pathway inhibitor ; Patient treat one prior chemotherapy regimen recurrent/metastatic disease Patient symptomatic CNS metastasis . Patients asymptomatic CNS metastasis may participate trial . The patient must complete prior local treatment CNS metastases ≥ 28 day prior start study treatment ( include radiotherapy and/or surgery ) must stable low dose corticosteroid therapy ; Patient recover ≤ grade 1 ( except alopecia ) relate side effect prior antineoplastic therapy Patient follow cardiac abnormality : symptomatic congestive heart failure , history document congestive heart failure ( New York Heart Association functional classification IIIIV ) , document cardiomyopathy , Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % determined Multiple Gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) ; myocardial infarction ≤ 6 month prior enrolment , unstable angina pectoris , serious uncontrolled cardiac arrhythmia , symptomatic pericarditis , QTcF &gt; 480 msec screen ECG ( use QTcF formula ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>platinum pre-treated recurrent metastatic</keyword>
	<keyword>Head neck squamous cell carcinoma ,</keyword>
	<keyword>recurrent</keyword>
	<keyword>metastatic</keyword>
	<keyword>BKM120</keyword>
</DOC>